In my functional medicine practice, I combine conventional and integrative strategies to address multiple aspects of SFN: Addressing Root Causes Even when using IVIG, it's crucial to identify and address any underlying factors that may have triggered or perpetuate the neuropathy: Autoimmune conditions Infections (Lyme, viral, etc.) Toxin exposures Nutritional deficiencies Metabolic issues Gut dysfunction Stress and trauma Complementary Therapies Several complementary approaches can enhance the benefits of IVIG: Alpha-lipoic acid B vitamins, particularly B1, B6, and B12 Anti-inflammatory herbs like turmeric and boswellia Low-dose naltrexone (LDN) Red light therapy Acupuncture Mind-body practices Lifestyle Modifications Supporting overall nerve health through: Anti-inflammatory diet Blood sugar regulation Stress management Gentle, appropriate movement Quality sleep Environmental toxin reduction Supporting Nerve Health with Targeted Supplementation For patients with small fiber neuropathy, whether receiving IVIG or not, I often recommend targeted nutritional support to promote nerve healing and function: Glutathione Essentials Glutathione is our master antioxidant and plays a critical role in nerve health and protection from oxidative damage
I would be on branded if it were available to me, and consistently
Nootropic supplements may have one ingredient, or they may have dozens
Klf15 suppresses cell proliferation and extracellular matrix expression in mesangial cells under high glucose
the 20% threshold was not part of the statistical testing hierarchy) Among the participants for whom data were available at the week 68 visit (1212 participants in the semaglutide group and 577 in the placebo group), these thresholds were reached by 86.4% (1047 participants), 69.1% (838 participants), 50.5% (612 participants), and 32.0% (388 participants), respectively, in the semaglutide group, as compared with 31.5% (182 participants), 12.0% (69 participants), 4.9% (28 participants) Participants who received semaglutide had a greater improvement with respect to cardiometabolic risk factors and a greater increase in participant-reported physical functioning from baseline than those who received placebo
